Duchenne Muscular Dystrophy (DMD)

Phase 3 Clinical Trial for Eteplirsen Now Enrolling Boys with Duchenne Muscular Dystrophy

Boys with Duchenne muscular dystrophy between the ages of seven and 16 are now being recruited to participate in a phase 3 clinical trial to evaluate the effectiveness and safety of eteplirsen in treating DMD.

DMD: Sarepta Updates Community on Eteplirsen, Other Compounds

First Drug for Duchenne Muscular Dystrophy Gets 'Conditional Approval' in Europe

DMD: Ataluren Receives Conditional Approval in Europe

PTC Therapeutics Receives Conditional Approval in the European Union for Translarna™ for the treatment of Nonsense Mutation Duchenne Muscular Dystrophy

DMD: ReveraGen Drug Will Move to Human Testing

International Consortium Provides $2M Funding for Phase 1 Clinical Trial of ReveraGen DMD Drug

DMD: Eteplirsen Data Still Encouraging at 144 Weeks

Sarepta Therapeutics Reports Long-Term Outcomes from Phase IIb Study of Eteplirsen

DMD: HT-100 Trial Has Reopened

Pages